Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Tight liquidity NBB
Cash and receivables cover 3 % of short-term debt in 2025; threshold 65 %.
Financials
Financial year 2025
HENRY PHARMA from Pont-à-Celles, company number BE0688865294, closed financial year 2025 with a result of € 60,103 after tax. For that financial year HENRY PHARMA recorded a gross margin of € 108,805 and equity of € 1.1 million. Compared with financial year 2024, the result moved from € 69,772 to € 60,103. The company is profitable. The buffer is growing. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on June 1, 2026.
€ 1.1 million
▲ 6% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 60,103
▼ 14% vs 2024
Profit after tax over the fiscal year.
€ 422
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 329,543.
Debts at end 2025
€ 837,639
▼ 11% vs 2024
€ 107,921 is repaid this year. At this pace the long-term loan is gone in ≈ 8 years.
€ 1,708
▲ 88% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 10,386
▼ 14% vs 2024
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 82,165 | € 124,798 | € 119,020 | € 108,805 | ▼ 9% |
| Profit after taxes | € 32,202 | € 73,373 | € 69,772 | € 60,103 | ▼ 14% |
| Equity | € 926,296 | € 999,668 | € 1,069,440 | € 1,129,543 | ▲ 6% |
| Total debts | € 2,684,676 | € 2,616,586 | € 2,542,245 | € 2,504,764 | ▼ 1% |
| Cash | € 39,402 | € 4,643 | - | € 422 | |
| Retained profit | € 126,296 | € 199,668 | € 269,440 | € 329,543 | ▲ 22% |
| Bank debt | € 1,140,344 | € 1,047,920 | € 944,800 | € 837,639 | ▼ 11% |
| Balance sheet total | € 3,610,972 | € 3,616,254 | € 3,611,685 | € 3,634,307 | ▲ 1% |
Key figures of HENRY PHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to HENRY PHARMA?
What happened at HENRY PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 60,103 (▼ 14% vs 2024). Source: NBB ↗
- New establishment in Pont-à-Celles. KBO
- Start of the company according to the CBE. KBO
- STEPHANE HENRY became a director. NBB
In short
From € 32,202 profit in 2022 to € 60,103 profit in 2025.
Paid € 76,652 in corporate taxes since 2022.
Best year ever: 2023, with € 73,373 profit.
Management
Behind HENRY PHARMA is STEPHANE HENRY. It owns 100% of PHARMACIE HENRY itself.
Directors
According to the 2025 annual accounts
since 2018
Establishments
Establishment units
Physical locations of this company
Rue Roosevelt(LUT) 29
6238 Pont-à-Celles
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0688.865.294
- VAT number
- BE 0688.865.294
- Registered office
- Rue Roosevelt(LUT) 29, 6238 Pont-à-Celles
- Names & denominations
- HENRY PHARMA
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 25 January 2018
- Peppol
- Active · Active since 31 Jul 2025
- Activities · NACE
Activiteiten van holdings
Holdings